RGNX Stock Summary and Trading Ideas (Regenxbio | NASDAQ:RGNX)

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Regenxbio trades on the NASDAQ stock market under the symbol RGNX.

As of March 5, 2026, RGNX stock price declined to $8.62 with 202,905 million shares trading.

RGNX has a beta of 2.30, meaning it tends to be more sensitive to market movements. RGNX has a correlation of 0.20 to the broad based SPY ETF.

RGNX has a market cap of $436.37 million. This is considered a Small Cap stock.

Last quarter Regenxbio reported $30 million in Revenue and -$1.20 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.13.

In the last 3 years, RGNX traded as high as $28.80 and as low as $5.04.

The top ETF exchange traded funds that RGNX belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.

RGNX has outperformed the market in the last year with a price return of +45.6% while the SPY ETF gained +19.8%. However, in the short term, RGNX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -33.6% vs +0.2% return in SPY. But in the last 2 weeks, RGNX shares have fared better than the market returning +9.1% compared to SPY -0.4%.

RGNX support price is $8.69 and resistance is $9.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGNX shares will trade within this expected range on the day.